Boots

Retailer / private label

A British health, beauty and pharmacy retailer combining community pharmacy services with beauty, personal-care and wellness products.

Last updated October 17, 2026

AI crawler reads

7requests

1companies

Anthropic7

Profile: 2
Controversies: 2
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Boots is a British health and beauty retailer and pharmacy chain whose roots extend to 1849, when John Boot established a herbal-medicine business in Nottingham. The company developed from a small retail operation into one of the United Kingdom’s best-known consumer health brands, with stores ranging from local pharmacies to large health and beauty outlets in high streets, shopping centres and other retail locations. Its principal activities include prescription dispensing, over-the-counter medicines, cosmetics, skincare, toiletries, vitamins, personal-care products and selected food and wellness goods. Many shops also provide optician, hearing-care and other health-related services, while the Boots website extends the brand’s reach through e-commerce and digital services. The company’s early growth was shaped by John Boot’s son Jesse Boot, who helped operate the family business after his father’s death. The business was incorporated in the nineteenth century, became Boots Pure Drug Company, and later expanded its retail, manufacturing and research activities. Boots was involved in the development of ibuprofen during the 1960s, although the company subsequently reduced its exposure to prescription-drug research and manufacturing. It also built a substantial portfolio of private-label products and services, including No7 beauty products, Boots Pharmaceuticals medicines and Boots Opticians. Boots pursued several diversification strategies during the twentieth century. It acquired the Timothy Whites and Taylors chain, expanded internationally, created Boots Opticians, experimented with larger-format stores and entered businesses such as automotive retail, do-it-yourself retail, dentistry and wellbeing services. Some of these activities were later sold or discontinued as the company refocused on pharmacy, beauty and health retail. Boots’ lending-library operation, present in many branches from the late nineteenth century until the 1960s, was an earlier example of the chain using its stores to provide services beyond medicines. Corporate ownership changed substantially in the twenty-first century. The Boots Company merged with Alliance UniChem in 2006 to create Alliance Boots. In 2007, Alliance Boots was acquired by Kohlberg Kravis Roberts and Stefano Pessina and taken private. Walgreens bought an initial 45 percent stake in 2012 and completed the acquisition of the remaining interest in 2014, creating Walgreens Boots Alliance. Boots subsequently operated as the group’s principal United Kingdom retail brand. In 2025, Walgreens Boots Alliance was acquired by Sycamore Partners, after which Boots was separated into a standalone private group identified as The Boots Group, alongside other former international assets. In the United Kingdom and Ireland, Boots remains one of the largest pharmacy and health-and-beauty retailers. Its customer proposition combines professional pharmacy access, a broad branded and own-label assortment, beauty expertise and a nationwide store network. The Boots Advantage Card loyalty programme, online shopping and services such as prescription management support an increasingly integrated store-and-digital model. At the same time, the company has faced criticism concerning pharmacy staffing, dispensing safety, NHS pricing, homeopathic products and the retail price of emergency contraception. These controversies have contributed to continuing public scrutiny of the balance between commercial targets and Boots’ responsibilities as a healthcare provider.

History

Boots began in Nottingham in 1849 as a herbal-medicine business established by John Boot. Following John Boot’s death, his young son Jesse helped his mother manage the shop. Jesse later developed the business into a more systematic retail operation, emphasizing accessible medicines and a growing branch network. The company was incorporated as Boot and Co. in 1883 and adopted the Boots Pure Drug Company name in 1888. The business expanded beyond retail into manufacturing and pharmaceutical research. In 1920, Jesse Boot sold the company to the American United Drug Company, but deteriorating economic conditions led to its return to British ownership in 1933. The company later became The Boots Company. During the twentieth century, many Boots branches also hosted Boots Book-Lovers’ Library departments, an unusual service that operated from 1898 to 1966. Boots acquired the Timothy Whites and Taylors chain in 1968 and expanded its international presence, including an entry into Canada through the acquisition of Tamblyn Drugs in 1979. The company also developed medicines and pharmaceutical technologies. Ibuprofen was developed by Boots researchers John Nicholson and Stewart Adams during the 1960s and later became one of the best-known products associated with the company’s scientific heritage. Boots received a Queen’s Award for Technical Achievement in 1987. Its later prescription-drug research programme included Manoplax, but safety concerns led to that product’s withdrawal in 1993. Boots subsequently sold its prescription-drugs division to BASF in 1994 and disposed of the Nurofen brand in 2006. The company diversified heavily in the late twentieth century. It opened a manufacturing plant at Cramlington in 1982, established Boots Opticians in 1987, acquired Halfords in 1991 and operated the Children’s World format for a period. It also entered dentistry and launched a broad wellbeing concept involving services such as facials, homoeopathy, nutritional advice, laser-eye surgery and Botox. Many of these ventures were later sold or closed, including the disposal of Halfords in 2002, the ending of the wellbeing initiative in 2003 and the sale of the laser-eye-surgery business in 2004. Boots Opticians later acquired Dollond & Aitchison in 2009. A decisive corporate transformation began with the merger of Boots and Alliance UniChem. Announced in 2005 and completed in 2006, the transaction created Alliance Boots. In 2007, Kohlberg Kravis Roberts and Stefano Pessina acquired Alliance Boots for £11.1 billion, taking the company private. The group moved its headquarters to Zug, Switzerland, in 2008, while the British retail business was re-registered as Boots UK Limited in 2007. Walgreens acquired 45 percent of Alliance Boots in 2012 and exercised its option to buy the remainder in 2014. The transaction created Walgreens Boots Alliance, with Boots continuing as its British pharmacy and health-and-beauty retail brand. During this period, Boots expanded its digital retail presence, operated the Advantage Card loyalty programme and continued to develop own-label products such as No7 and Boots Pharmaceuticals. The brand also encountered sustained criticism. In 2009, a Boots pharmacist told a parliamentary committee that the company sold homeopathic products despite lacking evidence of efficacy, citing consumer choice. In 2016, pharmacists and commentators raised concerns about staffing, targets and medicine-use reviews. Further controversies involved emergency-contraception pricing in 2017, NHS charges for certain products in 2018 and reported dispensing-safety and workplace-pressure concerns. Boots announced a substantial store-rationalisation programme in 2019, reflecting pressure on physical retail and changing consumer behaviour. In 2025, Walgreens Boots Alliance was acquired by Sycamore Partners. Boots was separated from the former listed group and became part of The Boots Group, a standalone private company owned by Sycamore Partners together with Stefano Pessina and his family. The modern Boots business remains centered on United Kingdom and Irish pharmacy, health, beauty and digital retail, while its wider group has additional international operations and investments.

2025
Boots becomes part of The Boots Group
[1]Boots (company)en.wikipedia.org
Following Sycamore Partners’ acquisition of Walgreens Boots Alliance, Boots is separated into a standalone private group.
2019
Store rationalisation begins
[1]Boots (company)en.wikipedia.org
Boots announces the closure of more than 200 underperforming stores.
2014
Walgreens Boots Alliance is established
[1]Boots (company)en.wikipedia.org
Walgreens completes the acquisition of Alliance Boots.
2007
Alliance Boots becomes private
[1]Boots (company)en.wikipedia.org
KKR and Stefano Pessina acquire Alliance Boots.
2006
Alliance Boots is created
[1]Boots (company)en.wikipedia.org
Boots merges with Alliance UniChem.
1987
Boots Opticians is formed
[1]Boots (company)en.wikipedia.org
Boots creates its optical retail business through acquisitions.
1968
Timothy Whites and Taylors is acquired
[1]Boots (company)en.wikipedia.org
Boots expands its British branch network through the purchase of the 622-store chain.
1888
The Boots Pure Drug Company name is adopted
[1]Boots (company)en.wikipedia.org
The company adopts a name reflecting its growing pharmaceutical and manufacturing activities.
1883
Boot and Co. is incorporated
[1]Boots (company)en.wikipedia.org
The family business is formally incorporated.
1849
John Boot establishes the business
[1]Boots (company)en.wikipedia.org
John Boot opens the herbal-medicine business in Nottingham that develops into Boots.

Products and positioning

A mainstream-to-premium health, beauty and pharmacy retailer built around professional pharmacy access, trusted own-label products, beauty expertise and convenient omnichannel shopping.

Skincare and beauty
No7
No7 is Boots’ best-known beauty and skincare brand. Its portfolio includes serums, moisturisers, anti-ageing products and cosmetics. The brand has been supported by scientific and clinical claims, including research into the effects of its Protect & Perfect serum, which received extensive media attention in 2007.
Over-the-counter medicines
Boots Pharmaceuticals
Boots Pharmaceuticals is the retailer’s own-label medicines range. It covers common health needs such as pain relief, coughs and colds, digestive health and other over-the-counter treatments. The range supports Boots’ positioning as both a pharmacy operator and a branded health retailer.
Optical services · 1987
Boots Opticians
Boots Opticians provides eye examinations, spectacles, contact lenses and related optical services through locations connected with Boots stores and through standalone practices. The business was created in 1987 and expanded through acquisitions, including Dollond & Aitchison in 2009.
Pharmacy services · 1849
Boots Pharmacy
Boots pharmacies dispense prescriptions and provide advice, over-the-counter medicines and selected clinical services. Pharmacy counters are central to the chain’s identity and distinguish it from a conventional beauty or general-merchandise retailer.
Loyalty programme
Boots Advantage Card
The Boots Advantage Card is the retailer’s loyalty programme. It links customer rewards and promotional activity across stores and digital channels, supporting repeat purchases and the integration of pharmacy, beauty and general health retail.

Controversies

2021
Boots recalls more than 30 products due to contamination
Boots recalled more than 30 products, including pregnancy vitamins, after contamination with 2-chloroethanol was identified. The Food Safety Authority of Ireland said consumption did not pose an acute health risk, but continued consumption over a long period could increase risk.
Source
2021
Boots recalls multivitamins over packaging error
Boots recalled multivitamin supplements that were incorrectly packaged: vitamin K was absent and iron had been added instead. The recall affects products sold from January 12 to 19, 2021.
Source
2019
Boots among retailers recalling products after food safety alerts
In September 2019, Asda, Boots and Waitrose recalled products following alerts issued by the Food Standards Agency. The source reporting the recalls does not identify the specific products involved, nor does it provide further details about the associated health risks. The event is recorded as a product recall by the three retailers in response to the agency's alerts, with no additional information available on the scope, cause, or outcome of the recalls.
Source
2018
Concerns over NHS product pricing
Media investigations reported very high prices charged to the NHS for certain products, including moisturiser and medicinal mouthwash. Boots rejected the characterization as overcharging and attributed the figures to bespoke orders, short notice and supply arrangements involving Alliance Healthcare.
Source
2018
Dispensing safety and staffing concerns
A BBC investigation discussed dispensing errors, patient deaths and accounts from whistleblowers who alleged inadequate staffing. A later coroner’s inquest found that a 2016 dispensing error contributed to the death of a patient.
Source
2017
Emergency-contraception pricing dispute
The British Pregnancy Advisory Service criticised Boots for charging substantially more than cost for emergency contraception and initially declining to adopt a cheaper option. Campaigners also objected to the company’s explanation that it received complaints from people opposed to the medicine.
Source
2016
Pharmacy targets and workplace pressure
Pharmacists and professional representatives alleged that Boots’ performance targets, medicine-use-review expectations and staffing levels placed pressure on staff and could conflict with professional duties. The controversy was followed by the departure of UK operations director Simon Roberts.
Source
2009
Sale of homeopathic products
A Boots superintendent pharmacist told a parliamentary science committee that the company had no evidence that its homeopathic products were effective, while continuing to sell them on the basis of consumer choice. The position attracted criticism and public protest.
Source

2019Women’s football sponsorship
England · Scotland · Wales · Northern Ireland · Republic of Ireland
Boots announced a three-year sponsorship of the women’s national football teams of the United Kingdom nations and the Republic of Ireland, covering major women’s football competitions including the 2019 World Cup period and planned Euro 2021 activity.
Outcome. The agreement positioned Boots alongside women’s sport and extended its consumer-health and beauty marketing beyond traditional retail advertising.
Source

Brand decisions

2025
Separate Boots from Walgreens Boots AllianceM&A
Background
Walgreens Boots Alliance was acquired by Sycamore Partners as part of a wider ownership restructuring.
Action taken
Boots was spun off into The Boots Group as a standalone private company.
Aftermath
Boots became owned by Sycamore Partners together with Stefano Pessina and his family.
Walgreens Boots Alliance acquisition value. US$10 billion (2025)
Source
2019
Rationalise the store estateStrategy
Background
Boots faced pressure from changing shopping habits, online competition and underperforming physical locations.
Action taken
The company announced the closure of more than 200 underperforming shops.
Aftermath
The announcement marked a significant retrenchment of the store network while Boots continued to operate a large UK and Irish estate.
Source
2012
Sell a minority stake to WalgreensM&A
Background
Walgreens and Alliance Boots pursued a long-term combination of their retail and international capabilities.
Action taken
Walgreens acquired 45 percent of Alliance Boots and obtained an option to purchase the remainder.
Aftermath
Walgreens completed the full acquisition in 2014.
Initial stake purchase. US$6.7 billion (2012)
Source
2007
Take Alliance Boots privateM&A
Background
Alliance Boots received a bid from a consortium led by KKR and Stefano Pessina.
Action taken
The consortium acquired Alliance Boots and removed it from the public market.
Aftermath
The deal made Alliance Boots the first FTSE 100 company acquired by a private-equity firm and shifted group headquarters to Switzerland.
Acquisition value. £11.1 billion (2007 acquisition)
Source
2006
Merge with Alliance UniChemM&A
Background
Boots sought a larger international platform and broader pharmaceutical distribution capabilities.
Action taken
The Boots Company merged with Alliance UniChem to create Alliance Boots.
Aftermath
The transaction created the corporate group that was later acquired by Walgreens.
Source

Recent events

Unconfirmed
Weston family agrees $8.9 billion deal to buy Boots[6]韦斯顿家族同意以89亿美元收购英国Bootsmiddleeaststar.com
Britain's Boots is set to come under the control of Canada's Weston family in an agreed $8.9 billion deal that includes the pharmacy business.
Unconfirmed
Reported2026.10.09
Wittington Investments agrees £7bn deal to acquire Boots[7]Wittington Investments 达成70亿英镑收购Boots的交易bbc.co.uk
A £7bn deal agreed this week makes Wittington Investments, the holding company of Canada's Weston family, the new owner of UK pharmacy and retail chain Boots, which operates around 1,800 UK stores. The article outlines possible effects on Boots' store revamps, its Advantage loyalty card and its expanding healthcare services.
2026.10.07
Reported2026.10.08
Wittington Investments to acquire Boots for US$8.9bn (£6.7bn)[8]Wittington Investments 宣布以89亿美元(67亿英镑)收购Bootspharmaceutical-journal.com
Wittington Investments, the holding company of the Canada-based Weston family, announced on 7 October 2026 an agreement to acquire Boots' retail operations in the UK and Ireland and associated businesses for US$8.9bn (£6.7bn) including assumed debt, from Stefano Pessina and his family and private equity firm Sycamore Partners, which became the majority owner in 2025. The sale is expected to complete in early 2027, after which Wittington chairman Galen Weston will become chairman of Boots.
Unconfirmed
Reported2026.10.07
Boots set to be taken over in £6.7 billion deal by billionaire family[9]英国连锁药房Boots将以67亿英镑被亿万富翁家族收购burnhamandhighbridgeweeklynews.co.uk
UK high street pharmacy chain Boots is set to be taken over in a deal worth £6.7 billion by an unnamed billionaire family. The report discusses what the takeover means for customers and staff at Boots stores in Somerset, England.
2026.10.07
Reported2026.10.07
Wittington Investments agrees to buy Boots in $8.9bn deal from Sycamore Partners and the Pessina family[10]Wittington Investments同意以89亿美元从Sycamore Partners及Pessina家族手中收购Bootsbbc.co.uk
On 7 October 2026, Wittington Investments, the holding company of Canada's billionaire Weston family, confirmed it had agreed to buy UK High Street pharmacy and retail chain Boots in an $8.9bn (£6.7bn) deal from US private equity firm Sycamore Partners and the Pessina family, having secured ownership in partnership with Fairfax Financial Holdings. The Weston family will buy Boots' retail operations in the UK and Ireland, Boots Opticians, No7 Beauty Company and its Thailand and franchised businesses, with completion set for early 2027; Sycamore Partners, in partnership with Stefano Pessina and his family, will retain ownership of Farmacias Benavides in Mexico and Alliance Healthcare Deutschland in Germany. Wittington chairman Galen Weston will become chairman of Boots.
2026.08.06
Reported2026.08.11
Boots UK launches private gonorrhoea vaccination service[11]Boots UK推出私人淋病疫苗接种服务pharmaceutical-journal.com
Boots UK launched a private gonorrhoea vaccination service at 160 of its pharmacies, available to people aged 18 and over and costing £220 for the full two-dose course, described as an option for adults who cannot access the vaccine via the NHS.
2026.08.05
Reported2026.08.11
Boots opens store at Belfast City Airport[12]Boots在贝尔法斯特城市机场开设门店travelextra.ie
Boots opened a new health, beauty and wellness store at Belfast City Airport on 5 August 2026, creating 13 permanent jobs plus additional seasonal opportunities.
2022.02.24
Reported2022.03.03
Sapphire Eye Care opens Romsey branch in partnership with Boots[13]Sapphire Eye Care与Boots合作开设罗姆西分店hampshirechronicle.co.uk
Sapphire Eye Care opened a new opticians branch in Romsey town centre in partnership with Boots. Its official opening was held on February 24.
2022.02.01
Reported2022.02.04
Boots reduces Morning After Pill service prices[14]Boots下调事后避孕药服务价格thetab.com
Boots reduced the price of its Morning After Pill service, with prices starting from £10 from February 1. The article identifies the service as including pharmacist consultation and advice.
2021.12.03
Reported2021.12.03
Boots recalls more than 30 products due to contamination[4]Boots recalls more than 30 products due to contaminationleinsterleader.ie
Boots recalled more than 30 products, including pregnancy vitamins, after contamination with 2-chloroethanol was identified. The Food Safety Authority of Ireland said consumption did not pose an acute health risk, but continued consumption over a long period could increase risk.

Sources35 sources

Cite this profile: Cite the canonical profile. /brand-wiki/boots · Editorial policy · How profiles are compiled